Overview
GLP-1 receptor single agonist, a peptide analog composed of 31 amino acids. It was approved by the FDA for type 2 diabetes in 2017 and will be approved for weight loss indications in 2021. It is currently one of the GLP-1 drugs with the highest market share.
| Chemical Class | GLP-1 receptor agonists |
| Dosage Form | Injection pen/oral tablet |
| Dosing Frequency | Once a week (injection) / once a day (orally) |
| Storage | Refrigerated at 2-8°C (injection)/room temperature (oral) |
Mechanism of Action
GLP-1 receptor activation: promotes glucose-dependent insulin secretion
Delayed gastric emptying: reduces postprandial blood sugar fluctuations
Central appetite suppression: acting on hypothalamic satiety signals
Related to indications: GLP-1 agonist with mature single-target mechanism and the most sufficient clinical data.
| Indication | Mechanism | Evidence |
|---|
| Blood sugar management support | GLP-1 receptor activation | Clinically approved |
| Weight management support | Gastric emptying + appetite suppression | Clinically approved |
| cardiovascular protection | Large clinical trial confirms MACE decline | Clinically approved |
Dosage & Administration
Data source: FDA approved instructions (Wegovy/Ozempic)/STEP clinical trial
Wegovy (Weight Loss): | Project | Content | Source of Evidence | |——|——|———-| | Recommended Dosage | Starting: 0.25 mg/week (Weeks 1-4) → 0.5 mg/week (Weeks 5-8) → 1 mg/week (Weeks 9-12) → 1.7 mg/week (Weeks 13-16) → 2.4 mg/week Maintenance | FDA Approved Inserts | | Route of Administration | Subcutaneous injection (abdomen, thigh, upper arm) | FDA-approved instructions | | Frequency | Once a week | FDA-approved instructions | | Duration | Long-term maintenance | Clinical trials |
Ozempic (T2DM): | Project | Content | Source of evidence | ——|——|———-| | Recommended dose | Starting: 0.25 mg/week (4 weeks) → 0.5 mg/week maintenance; if intensification is required, increase to 1 mg/week → Maximum 2 mg/week | FDA approved instructions | | Route of administration | Subcutaneous injection | FDA approved instructions | | Frequency | Once a week | FDA approved instructions |
Individualized adjustment: If 2.4mg is not tolerated, it can be reduced to 1.7mg for maintenance.
Safety Information
Regulatory Status
FDAApproved
NMPA (China)Status to be confirmed
WADAnot disabled
NotePlease add the regulatory status of each country
Drug Interactions
FAQ
Q1: How long will it take to see changes?
The change time varies greatly depending on the product mechanism and personal physique. It is recommended to refer to clinical trial data of similar products.
Q2: Will it rebound after deactivation?
Depends on product category and individual maintenance regimen. Metabolic products may gradually return to baseline; repair products are usually long-lasting.
Q3: Can it be used with other supplements?
In most cases, it is possible, but care should be taken to avoid overlapping products with the same mechanism. Please refer to Module 13 ‘Drug Interactions’ for details.
Q4: Why is it banned for athletes?
Some products are included in WADA’s banned list. Athletes should check the latest WADA list before use.
Q5: What is the difference from XX products?
Please see the competitor comparison matrix for this category.
Q6: Are there any side effects?
Please see Module 12 ‘Safety and Toxicology Details’.
Q7: Does it need to be used for a long time?
Depends on product category and target. Please refer to Module 10 ‘Dosage and Administration’ for treatment recommendations.
Q8: Who is not suitable?
Please refer to Module 8 ‘Contraindications and Precautions’.
Disclaimer: This product is intended for research purposes only. Not for human consumption or therapeutic use. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
